A Combination of Teclistamab and Daratumumab Prolongs PFS in Patients with Relapsed or Refractory Multiple Myeloma By Ogkologos - January 12, 2026 477 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MajesTEC-3 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Sacituzumab Govitecan Demonstrates a Relatively High ORR with Rapid Responses in... September 16, 2024 Imaging Test Could Help Guide Breast Cancer Treatment Decisions March 11, 2021 3 Steps to Making the Right Decisions for You During Cancer:... February 8, 2024 Heartburn Medications Pulled From Shelves Because They May Cause Cancer January 13, 2020 Load more HOT NEWS Trial Confirms CAR T-Cell Therapy Benefits People with Aggressive Lymphomas Cancer in My Community: Caring for the Whole Patient in Brazil Honeybee Venom May Be the Next Treatment for Aggressive Breast Cancer How to Cope With Waiting Periods During Cancer: An Expert Perspective
